Equecabtagene Autoleucel (Fucaso)
BCMA-targeting autologous CAR-T cell therapy for relapsed or refractory multiple myeloma, approved by China NMPA.
What is equecabtagene autoleucel (Fucaso)?
What it targets
BCMA (B-cell maturation antigen), a protein highly expressed on multiple myeloma cells. Targeting BCMA allows the CAR-T cells to selectively destroy myeloma cells.
Who it may help
Adults with relapsed or refractory multiple myeloma who have received three or more prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Why testing matters
Comprehensive organ function, infection screening, and myeloma disease assessment are required to confirm eligibility and safety before leukapheresis and CAR-T infusion.
Which cancers can equecabtagene autoleucel treat?
Equecabtagene autoleucel is currently approved in China for multiple myeloma. It is also being studied in other conditions.
| Relapsed or refractory multiple myeloma (3+ prior lines) | China NMPA-approved for adult patients after at least three prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent. Supported by the FUMANBA-1 pivotal study. |
| BCMA-positive myeloma biology | Designed to target BCMA on myeloma cells. BCMA is broadly expressed in multiple myeloma, making the majority of relapsed patients potentially eligible from a biomarker standpoint. |
| Investigational use — autoimmune disease | Equecabtagene autoleucel has been explored in autoimmune conditions such as neuromyelitis optica spectrum disorder in early-phase studies. This is separate from its approved myeloma indication. |
| Other myeloma settings (investigational) | Clinical trials are exploring its use in earlier lines of therapy and in combination with other myeloma treatments. Access outside the approved indication is only possible through clinical trials. |
Are you eligible for equecabtagene autoleucel?
Eligibility depends on myeloma status, prior treatment lines, organ function, fitness for the full CAR-T pathway, and ability to travel to and remain in China for treatment.
- Confirmed diagnosis of relapsed or refractory multiple myeloma
- Three or more prior lines of therapy already received
- Prior treatment must include at least one proteasome inhibitor
- Prior treatment must include at least one immunomodulatory agent
- Adequate organ function — kidney, liver, heart, and lung
- No active or uncontrolled infection at the time of leukapheresis
- Adequate bone marrow reserve to undergo lymphodepleting chemotherapy
- Disease stable enough to wait for manufacturing (or bridging therapy planned)
- Able to travel to China and remain near the CAR-T centre for monitoring
- Reliable adult caregiver available throughout the treatment and recovery period
How does equecabtagene autoleucel work?
- Step 1 — T cell collection (leukapheresis)
- Step 2 — Genetic modification and manufacturing
- Step 3 — Lymphodepleting chemotherapy
- Step 4 — CAR-T infusion
- Step 5 — CAR-T expansion and myeloma attack
- Step 6 — Monitoring and response assessment
Fucaso is the first fully human anti-BCMA CAR-T therapy approved by China's NMPA — personalised from your own T cells.
Tests required before equecabtagene autoleucel
These tests confirm eligibility, assess fitness for the full CAR-T pathway, and establish baselines for monitoring.
| Bone marrow biopsy and aspiration | Confirms active myeloma disease, plasma cell burden, cytogenetics, and FISH. Essential for eligibility and baseline risk assessment. |
| Myeloma protein markers | Serum protein electrophoresis, immunofixation, free light chains, and immunoglobulin levels to quantify and type the myeloma paraprotein. |
| Imaging — PET-CT, MRI, or CT | Assesses bone disease, extramedullary lesions, and lytic lesions. Baseline imaging is required for response evaluation after treatment. |
| Complete blood count (CBC) | Assesses baseline blood counts — critical for determining fitness for lymphodepletion and identifying active cytopenias. |
| Liver and kidney function tests | Organ function is required for safe lymphodepleting chemotherapy and overall CAR-T eligibility. Repeat testing during treatment. |
| Coagulation and inflammatory markers | Baseline CRP, ferritin, fibrinogen, D-dimer, and coagulation screen. Elevated markers may indicate early CRS risk. |
| Infection screening | Hepatitis B, hepatitis C, HIV, tuberculosis, and other centre-specific infection tests. Active infection must be treated before leukapheresis. |
| Heart and lung assessment | ECG and echocardiogram where indicated. Pulmonary function tests for patients with cardiorespiratory concerns. |
| Prior treatment history review | Documentation of all prior lines — proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, transplant, bispecifics, and prior BCMA therapy. |
| Pregnancy test and fertility counselling | Pregnancy test before leukapheresis and lymphodepletion. Fertility counselling and contraception discussion where relevant. |
How is equecabtagene autoleucel given?
Equecabtagene autoleucel is not a pill or a standard drug infusion — it is a personalised CAR-T cell therapy delivered through a multi-step process in an approved hospital.
| Administration route | Single intravenous (IV) infusion given in an experienced CAR-T centre after lymphodepleting chemotherapy. |
| Lymphodepletion before infusion | Fludarabine and cyclophosphamide are given for approximately 3 days before infusion to prepare the immune system and allow CAR-T cells to expand. |
| Infusion timing | Equecabtagene autoleucel is infused as a single dose on day 0, typically 2 days after the last lymphodepleting chemotherapy dose. |
| Bridging therapy | If myeloma is progressing during the manufacturing period, the treating team may give bridging therapy to control disease until the CAR-T product is ready. |
| Post-infusion monitoring stay | Patients must remain near the CAR-T centre for at least several weeks after infusion for daily monitoring of temperature, blood counts, organ function, and neurologic symptoms. |
| Duration of therapy | A single infusion — there is no maintenance or repeat dosing schedule for the CAR-T product itself. |
| Where it can be given | Only at hospitals approved to administer CAR-T therapies with CRS management protocols, ICU backup, neurology support, and 24-hour monitoring capability. |
| International patient pathway | For patients travelling to China, allow time for pre-treatment evaluation, leukapheresis, manufacturing, infusion, and post-infusion observation before returning home. |
Clinical evidence and potential benefits
The FUMANBA-1 pivotal study supported the China NMPA approval of equecabtagene autoleucel for relapsed or refractory multiple myeloma.
| FUMANBA-1 study support | The pivotal FUMANBA-1 clinical study provided the efficacy and safety evidence supporting the China NMPA conditional approval of Fucaso in June 2023 for heavily pre-treated multiple myeloma. |
| Deep myeloma response | CAR-T therapies targeting BCMA, including equecabtagene autoleucel, have demonstrated deep responses including complete responses and MRD negativity in selected patients with relapsed or refractory myeloma. |
| Single-infusion personalised approach | A one-time treatment made from the patient's own cells — potentially offering a treatment-free interval in responding patients without requiring ongoing daily oral therapy. |
| BCMA-directed precision | Directly targets BCMA on myeloma cells, providing a mechanism distinct from proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies that the patient has already received. |
| Option for heavily pre-treated patients | Provides a viable treatment pathway for patients who have exhausted several standard myeloma options and may have limited alternatives in their home country. |
| China access for international patients | Through a structured China corridor, eligible international patients can access a fully human anti-BCMA CAR-T option not yet widely available in other countries. |
Individual responses vary. These represent published clinical data and approved indications. Outcomes depend on disease biology, prior treatment history, organ function, and overall fitness.
Side effects of equecabtagene autoleucel
CAR-T cell therapy can cause serious and sometimes life-threatening side effects that require expert management in an experienced centre. Most side effects occur in the first few weeks after infusion.
| Cytokine release syndrome (CRS) | Very common. Fever, chills, low blood pressure, low oxygen, and rapid heartbeat. Graded from mild to severe. Managed with tocilizumab, steroids, and supportive care. |
| Neurologic toxicity (ICANS) | Confusion, speech difficulty, drowsiness, tremor, headache, and in severe cases seizures or reduced consciousness. Requires neurologic assessment and prompt management. |
| Neutropenia (low neutrophils) | Very common. Increases infection risk. May require G-CSF (growth factor support), antibiotics, and hospitalisation. Can be prolonged — lasting weeks to months. |
| Thrombocytopenia (low platelets) | Common. Risk of bleeding. May require platelet transfusions. Monitor closely with regular blood counts after infusion. |
| Anaemia (low red blood cells) | Common. Fatigue, breathlessness, pallor. May require red cell transfusions during recovery. |
| Severe infections | Bacterial, viral, and fungal infections including pneumonia, sepsis, and herpes reactivation. Risk is highest during neutropenic and hypogammaglobulinaemic periods. |
| Hypogammaglobulinaemia | Reduced immunoglobulin levels due to B-cell aplasia after BCMA targeting. Long-term risk factor for infections. May require IVIG replacement therapy. |
| Tumour lysis syndrome | Can occur in patients with high myeloma burden. Causes electrolyte imbalances and kidney strain. Managed with hydration, monitoring, and allopurinol. |
| Prolonged cytopenias | Low blood counts lasting weeks or months after infusion. May require transfusion support, growth factors, and extended monitoring even after initial recovery. |
| Infusion reactions | Fever, chills, or other reactions at time of infusion. Premedication and monitoring protocols are standard at approved CAR-T centres. |
Contact your doctor or go to hospital immediately if you develop:
- Fever above 38°C (100.4°F) at any time after CAR-T infusion
- Confusion, difficulty speaking, or any change in consciousness
- Severe difficulty breathing or very low oxygen level
- Uncontrolled shaking, seizure, or sudden severe headache
- Signs of severe infection: rigors, extreme fatigue, or rapid deterioration
- Unusual bleeding or bruising not explained by known low platelets
Safety precautions before and after equecabtagene autoleucel
Tell the full CAR-T team about all medical history, medicines, supplements, herbal products, and recent infections before starting the treatment process.
- Inform the team of all active infections, hepatitis B/C, HIV, tuberculosis exposure, and recent viral illnesses before leukapheresis
- Prior BCMA-targeted therapy (e.g. belantamab, other BCMA CAR-T or bispecific) must be disclosed — may affect eligibility or response
- Inform the team of all current medications, including anticoagulants, steroids, immunosuppressants, and supplements
- Pregnancy must be excluded before leukapheresis and lymphodepleting chemotherapy — use reliable contraception as advised
- Breastfeeding is not recommended during CAR-T treatment and for a period after infusion
- Live vaccines must not be given during CAR-T treatment or for the period advised by the treating team
- Corticosteroids and immunosuppressants used at the time of CAR-T infusion may impair expansion — discuss all medicines with the team
- Patients must not drive or operate heavy machinery during the post-infusion monitoring period due to risk of neurologic toxicity
- A reliable adult caregiver must be available throughout the hospital stay and post-infusion monitoring period
- Remain within easy reach of the CAR-T centre for at least the period specified by the treating team after infusion
Equecabtagene autoleucel and combination treatment
Equecabtagene autoleucel is given as a single-agent CAR-T infusion within a defined pathway. Pre- and post-infusion treatments are part of the same protocol.
| Lymphodepleting chemotherapy (pre-infusion) | Fludarabine and cyclophosphamide given 3–5 days before infusion. This is a required part of the CAR-T pathway, not optional. |
| Bridging therapy (if needed) | Myeloma-directed therapy may be given during the manufacturing period if disease is progressing. Choice of bridging agent is guided by prior treatment history and disease biology. |
| CRS and ICANS management agents | Tocilizumab and corticosteroids are the standard treatments for CRS and ICANS. These are given reactively and are part of the safety management protocol at the CAR-T centre. |
| IVIG replacement (post-infusion) | Intravenous immunoglobulin may be given for hypogammaglobulinaemia during recovery to reduce infection risk from B-cell aplasia. |
| Combination trials (investigational) | Clinical trials are studying equecabtagene autoleucel in combination with other myeloma therapies, bispecific antibodies, or in earlier treatment lines. Access is through clinical trial enrolment only. |
If equecabtagene autoleucel stops working
Myeloma can relapse after CAR-T therapy. Understanding the likely mechanisms guides the next treatment decision.
| BCMA antigen loss or downregulation | One of the most common mechanisms of relapse after BCMA CAR-T therapy. Myeloma cells may lose or reduce BCMA expression, making them no longer visible to the CAR-T cells. |
| CAR-T cell exhaustion or poor expansion | In some patients, the infused CAR-T cells do not expand adequately or become functionally exhausted over time, limiting their ability to sustain a response. |
| T-cell dysfunction at time of collection | If the patient's T cells were heavily treated or dysfunctional at leukapheresis, the manufactured product may have limited potency. |
| Next-line options after BCMA CAR-T relapse | Bispecific antibodies targeting non-BCMA targets (GPRC5D, FcRH5), non-BCMA myeloma regimens, clinical trials, and palliative care depending on performance status and myeloma biology. |
| Second opinion after CAR-T relapse | Strongly recommended. The best next treatment depends on speed of relapse, BCMA status, prior lines, marrow reserve, and available trials. CancerFax can help arrange a specialist myeloma second opinion. |
Cost of equecabtagene autoleucel
Equecabtagene autoleucel is a China-approved CAR-T therapy. Cost depends heavily on the CAR-T centre, manufacturing, hospital package, complications management, and for international patients, travel and logistics.
| China (approved hospitals) | The CAR-T product cost, hospital package, lymphodepletion, monitoring, and supportive care are billed separately. Total inpatient cost is significant. Some hospitals offer estimated packages — request a written breakdown. |
| International patients (China pathway) | Additional costs include medical translation, hospital pre-review, visa and travel, accommodation near the centre, caregiver costs, and potential emergency extension of stay for CRS or infection. |
| ICU and complication contingency | Severe CRS, ICANS, or infections requiring intensive care or prolonged hospitalisation can substantially increase the total cost. Factor this into financial planning. |
| Post-treatment follow-up | Response assessment, MRD testing, blood counts, IVIG, and long-term monitoring after returning home add to the overall cost of treatment. |
| Patient assistance and access support | CancerFax can help patients understand cost structures, compare hospitals, and plan financial logistics for a China CAR-T treatment pathway. |
Availability of equecabtagene autoleucel globally
Equecabtagene autoleucel is currently only approved in China. International patients can access it through a structured China treatment corridor with appropriate eligibility and travel planning.
China
NMPA-approved June 30, 2023. Available at selected accredited CAR-T centres. Developed by IASO Bio and Innovent. Hospital capacity and manufacturing slots may vary — early referral is recommended.
International (via China corridor)
Patients from India, the Middle East, Southeast Asia, and other regions can access treatment through a China corridor. CancerFax assists with eligibility review, hospital selection, visa, and travel coordination.
USA / Europe
Equecabtagene autoleucel is not approved in the USA or Europe as of mid-2026. Patients in these regions seeking BCMA CAR-T options should discuss approved local options or clinical trial access with their oncologist.
India
Not approved in India as of mid-2026. Indian patients seeking CAR-T therapy for myeloma may consider the China pathway through CancerFax or explore domestic clinical trial availability.
Equecabtagene autoleucel in clinical trials
Beyond its approved myeloma indication, equecabtagene autoleucel is being studied in additional settings and conditions.
| FUMANBA-1 pivotal trial | The registration study that supported China NMPA approval. Enrolled adults with relapsed or refractory multiple myeloma after multiple prior lines. |
| Autoimmune disease studies | Early-phase investigations in neuromyelitis optica spectrum disorder and potentially other BCMA-expressing autoimmune conditions. Separate from the myeloma indication. |
| Earlier lines of myeloma therapy | Studies exploring whether CAR-T can be used earlier in the myeloma treatment journey — before patients have exhausted three or more prior lines. |
| Combination and sequencing trials | Research on sequencing with bispecific antibodies, maintenance regimens, or transplant strategies to improve durability of CAR-T response. |
| Manufacturing optimisation | Ongoing work on improving manufacturing turnaround times, product quality, and making CAR-T more accessible to a broader patient population. |
Your treatment journey with equecabtagene autoleucel
Confirming relapsed or refractory myeloma
CAR-T eligibility assessment
Medical record review and hospital pre-approval
Travel, visa, and caregiver preparation
Leukapheresis (T cell collection)
Manufacturing and bridging therapy
Lymphodepleting chemotherapy
CAR-T infusion and close monitoring
Response assessment and discharge planning
Long-term monitoring after returning home
Questions to ask your oncologist about equecabtagene autoleucel
- Am I eligible for equecabtagene autoleucel based on my prior treatment history?
- Is my disease stable enough to wait for CAR-T manufacturing?
- What is my risk of cytokine release syndrome and how will it be managed?
- How long do I need to stay near the CAR-T centre after infusion?
- What happens if the CAR-T product cannot be manufactured from my T cells?
- What are my monitoring and follow-up requirements after returning home?
- Are there other BCMA or non-BCMA options I should compare before committing?
- Can CancerFax help coordinate access to the China CAR-T programme?
How CancerFax supports equecabtagene autoleucel patients
CancerFax specialises in helping myeloma patients access advanced cell therapies — including CAR-T treatment in China — through expert coordination and end-to-end support.
| Medical record review | Upload your bone marrow reports, myeloma markers, imaging, and prior treatment summary — our oncology team will review and advise on China CAR-T eligibility for equecabtagene autoleucel. |
| China hospital identification | We identify approved CAR-T centres in China experienced in equecabtagene autoleucel and connect you with the right hospital for your case and logistics. |
| Specialist second opinion | We arrange remote second opinions from China-based myeloma and CAR-T specialists who can review your case and provide a preliminary eligibility and treatment plan. |
| Travel and visa coordination | CancerFax supports international patients with visa letters, accommodation near the CAR-T centre, caregiver planning, and logistics for extended stay in China. |
| Home oncologist liaison | We coordinate communication between the China treating team and your home oncologist to ensure seamless follow-up after returning from treatment. |
| Cost and financial planning | We help patients understand the full cost of China CAR-T treatment — including hospital, manufacturing, ICU contingency, and post-treatment monitoring — and plan realistically. |
Frequently asked questions about equecabtagene autoleucel
Common questions from multiple myeloma patients and caregivers
Equecabtagene autoleucel, sold under the brand name Fucaso, is a CAR-T cell therapy approved in China for adults with relapsed or refractory multiple myeloma. It is made from the patient's own T cells, which are modified to recognise BCMA — a protein found on most multiple myeloma cells — and destroy them after infusion. It is approved for patients who have received at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Unlike chemotherapy, which kills rapidly dividing cells broadly, equecabtagene autoleucel is a personalised cell therapy made from the patient's own immune cells. It is engineered to specifically recognise BCMA on myeloma cells and attack them with precision. The treatment is given as a single infusion rather than repeated cycles, and it can expand inside the body after infusion to continue fighting the disease.
The full process typically takes four to six weeks from T-cell collection to infusion. After leukapheresis, the cells are shipped to a manufacturing facility where they are engineered and expanded, which usually takes two to four weeks. During this waiting period, some patients receive bridging therapy to control the lymphoma. Hospital monitoring after infusion can extend for several additional weeks.
The two most important safety warnings for sacituzumab govitecan are severe neutropenia (dangerously low white blood cells) and severe diarrhea, both of which can be life-threatening if untreated. You should contact your oncology team immediately if you develop fever, chills, severe diarrhea, signs of infection, or difficulty breathing. Regular blood count monitoring is required throughout treatment to catch neutropenia early.
Yes, international patients can explore access through a China treatment corridor with the help of a patient navigation service like CancerFax. The process involves sharing medical records for remote review by a China-based CAR-T specialist, obtaining a hospital eligibility opinion, planning travel and visa logistics, undergoing leukapheresis and manufacturing in China, and receiving the infusion and post-infusion monitoring at an approved hospital before returning home. Not every patient is suitable for this pathway — fitness for travel, infection status, and disease stability are key factors.
If myeloma returns after equecabtagene autoleucel, the treating team will assess the speed of relapse, BCMA expression status, marrow reserve, and prior treatment history to guide next options. These may include bispecific antibody therapy, non-BCMA targeted drugs, clinical trials, or palliative and supportive care depending on the clinical situation. A specialist second opinion is strongly recommended after CAR-T relapse. CancerFax can help arrange a second opinion consultation with a myeloma expert.
Yes. Sorafenib is available as generic versions in several countries, including India, where it has an important history linked to the country's first compulsory licence for a cancer drug. Generic sorafenib contains the same active ingredient at the same dose and has been used widely. Ask your oncologist or pharmacist about generic availability and legitimate sourcing in your country. CancerFax can also help with access guidance across India, China, and other regions.
BCMA expression is the primary target of equecabtagene autoleucel. While the drug is approved for relapsed or refractory multiple myeloma broadly — and BCMA is expressed on most myeloma cells — the treating team will review prior treatment history, disease burden, and biology to assess suitability. If you have previously received another BCMA-targeted therapy, the team may assess BCMA expression to inform the decision. Your oncologist will advise on what testing is needed in your specific case.